Finance News Archive

Enter a date to view that day's archives:

Showing 1-20 of 1505 stories from the past year.

Teva Pharmaceutical Industries Ltd. is buying San Diego-based Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.

The San Diego Stock Exchange Index closed higher Monday at 197.09, up 2.89 percent from Friday. Advancing issues beat decliners 62 to 31 and 88 issues were unchanged. Auspex Pharmaceuticals Inc. (Nasdaq: ASPX) was the top dollar gainer, up $29.45 to $100.36. Adamis Pharmaceuticals Corp. (Nasdaq: ADMP) was the top dollar loser, down $1.56 to $3.83. For the complete, updated San Diego Stock Exchange Index visit sddt.com/stocks.

Winding down the first quarter of 2015. As of Friday, it looked like the first three months of the year would go into the books with the major indexes posting modest declines as stock prices have seesawed through the quarter and the Dow industrials were down just 0.8 percent. Well, what a difference a day can make.

Major Economic Releases


Business and professional groups have a range of activities planned this week.

The San Diego County Parks and Recreation Department announced on Thursday new strategies to increase revenue and ensure the department is meeting the needs of residents.

San Diego-based real estate investment trust Realty Income Corp. is being be added to the S&P 500 index.

The San Diego Stock Exchange Index closed higher Friday at 191.55, up 1.74 percent from Thursday. Advancing issues beat decliners 59 to 31 and 91 issues were unchanged. Receptos Inc. (Nasdaq: RCPT) was the top dollar gainer, up $8.44 to $147.43. Vital Therapies Inc. (Nasdaq: VTL) was the top dollar loser, down 51 cents to $25.50. For the complete, updated San Diego Stock Exchange Index visit sddt.com/stocks.

Hardly a year goes by that there isn’t some type of legislation or regulation proposed to address abusive short-term lending programs often referred to as payday loans. This year is no different.

I explained last week that new-home sales — 539,000 on an annual basis — came in far higher than the estimate of 462,000.

Four in a row. Yes, this has not been a stellar week for stocks as the Dow industrials have declined every day this week. Yesterday's loss was just 41 points but a loss is a loss. Still, even with the string of down days, the blue chip index is still off just 0.8 percent since the start of the year.

Major Economic Releases

Every time Susanna P. Starcevic takes on a new client, she starts a new journey.

It doesn't take long when speaking with Anneke Stender, executive vice president of TAG, to notice her deep-seeded passion for her work. "I never come to work thinking, ‘Oh, I'm going to work,'" she said. "I love what I do".

Clients of Sandy Coventry would probably be surprised to know that she overcame great shyness as a youngster to become the gregarious, helpful and dedicated employee benefits consultant she is today with Wateridge Insurance Services.


Home prices are rising, but incomes aren’t keeping pace.

Sempra Energy is planning to create a separate company to hold natural gas and renewable power assets, and then sell shares in an initial public offering.

The San Diego Stock Exchange Index closed higher Thursday at 188.27, up 0.1 percent from Wednesday. Declining issues beat advancers 46 to 44, and 91 issues were unchanged. Auspex Pharmaceuticals Inc. (Nasdaq: ASPX) was the top dollar gainer, up $3.22 to $68.84. Sempra Energy (NYSE: SRE) was the top dollar loser, down $2.28 to $107.17. For the complete, updated San Diego Stock Exchange Index, visit sddt.com/stocks.

Conatus Pharmaceuticals Inc. announced top-line results from its Phase 2 double-blind, placebo-controlled clinical trial of emricasan, a first-in-class, orally active pan-caspase protease inhibitor, in 38 patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with nonalcoholic steatohepatitis, and Orexigen Therapeutics Inc. announced that the European Commission has granted marketing authorization for Mysimba as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients over 18 years old with an initial Body Mass Index of obese or overweight in the presence of one or more weight-related co-morbidities, according to company announcements, SEC filings and Bloomberg News.

Grab on to something and hold on tight. Yes, the big correction, six years overdue, apparently has arrived. The Los Angeles Times headline this morning screams, "Stocks sink for a third straight day." I wonder what the headline would be if stocks had been up for three days.

Subscribe Today!